An antibody against bone metastases divides their frequency by 100
Published the 19.12.2017 at 15h38
The research wanted to understand how the tumor cells and the bone cells communicate between each other via means of molecular signaling. Previous work in the laboratory had shown that a molecule called “Jagged1” was an essential element of this two-directional relationship between these cells while facilitating the installation of the bone metastasis.
A polyclonal anti-Jagged1
The expression “Jagged1” to the cell surface of bone, the osteoblasts, is increased in the course of chemotherapy. It is a medium that allows cancer cells to escape chemotherapy.
It is now possible to reduce the risk of bone metastasis using an antibody called “15D11” which target and block the protein “Jagged1” and therefore limited the metastasis to the bone. Researchers at Princeton University have demonstrated in a study published in the journal Cancer Cell.
In the experiments conducted by the team of Pr. Yibin Kang, the mouse with a treatment that combines antibodies and chemotherapy have remained in good health. In fact, the tumor burden in bone was decreased more than 100-fold with the combined treatment.
To the human trials
“Jagged1” acts at the level of osteoblasts by protecting the tumor cells in the bone. In this framework, 15D11 is specifically intended to target “Jagged1” because the antibody allows the chemotherapy to continue to fight the cancer.
The team hopes to be able to quickly get permission for human trials. Since the antibody is 100% man-made, the next step is to conduct clinical trials in patients.
“This work represents an important step forward for medical research, in the eyes of professor Russell S. Taichman, University of Michigan. The development of a new therapeutic target (Jagged1), useful in the sick people, can change the clinical perspective for patients with early disease and for those with metastases, diffuse “.